DHODH and cancer: One explanation for this synergy between DHODH inhibitors and mdm2 inhibitors is that if cancer cells treated with DHODH inhibitors accumulate in S phase, releasing p53 from mdm2 at this vulnerable stage of the cell cycle may promote cell death.